Independent Development of Novel Drugs

Integrate partner company’s drug candidates with KOLON PHARMA’s unique novel target to formulate high-probability drug candidates

Identified 50+ novel targets from two indications (Pancreatic cancer and Ovarian cancer) via the PRIINT Platform, holding the most anti-cancer targets among Korean firms

Joint Development of Novel Drugs

Offer KOLON PHARMA’s R&D prowess with mutually shared responsibilities and ownership of drug candidates to elevate success rates

Reposition partner’s drug leveraging KOLON PHARMA’s translational research expertise

Pre-clinical/Clinical Translational Research/Clinical Test Consulting

Services catered to both domestic and international sponsors

Instances of evolving a client relationship into a joint development partnership

Emphasis on Orthotopic transplant model/Clinical translational research

Focus on regimen development and indication expansion

Offer Reentry Reposition Consulting and Reverse Translation